NASDAQ · ERAS
Erasca, Inc.
$14.98-$0.14 (-0.93%)
Erasca, Inc.’s quoted price sits in the upper half of its reported 52-week range, 38.3% below the high.
Loading market information…
NASDAQ · RVMD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Revolution Medicines, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.18% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Revolution Medicines, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$2.35. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Revolution Medicines, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | -$1.13-0.89% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | -$1.12-10.89% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | -$0.94-5.62% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
25 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 17 contributors · Median target $260.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$14.98-$0.14 (-0.93%)
Erasca, Inc.’s quoted price sits in the upper half of its reported 52-week range, 38.3% below the high.
$19.47-$0.22 (-1.12%)
Relay Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.46% below the high.
$22.53+$0.30 (+1.35%)
Tango Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.49% below the high.
$45.08+$0.30 (+0.67%)
Enliven Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
$32.89-$1.07 (-3.15%)
IDEAYA Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.94% below the high.
$27.12-$0.14 (-0.51%)
Nurix Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
$8.99-$0.31 (-3.33%)
ORIC Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.76% below the high.
$10.87+$0.02 (+0.18%)
Monte Rosa Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.82% below the high.
